AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with congenital degenerative diseases | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with congenital degenerative diseases


Duchenne muscular dystrophy (DMD) is one of the most common congenital diseases in the world, affecting one in 3,500 Canadian males. DMD is caused by mutations in the dystrophin gene that results in progressive muscle degeneration and there are currently no effective treatments for DMD. In an effort to fulfill this unmet medical need, AbCellera Biologics Inc. has entered into a three-year partnership with Drs. Fabio Rossi and Michael Underhill of the University of British Columbia (UBC) to discover, test, and develop therapeutic antibodies for the treatment of Duchenne Muscular Dystrophy-associated fibrosis.

https://www.duchennexchange.org/wp-content/uploads/2018/08/AbCellera_Full_Colour_RGB_1.jpg